ArticleCancer2015
Health care utilization and end-of-life care for older patients with acute myeloid leukemia.
Article in Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 4 syntheses or guidelines pooled it, 144 citations in OpenAlex.
- Supportive care interventions in hematopoietic stem cell transplantation: a systematic review and meta-analysis.Blood advances · 2026Pooled it
- A systematic review of health state utility values for older people with acute myeloid leukaemia.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Pooled it
- Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review.PloS one · 2021Pooled it
- Duration of palliative care before death in international routine practice: a systematic review and meta-analysis.BMC medicine · 2020Pooled it
- A pilot randomized clinical trial of a peer support intervention for hematopoietic stem cell transplantation.Blood advances · 2026Trial
- Trial
- A Positive Psychology Intervention in Allogeneic Hematopoietic Stem Cell Transplantation Survivors (PATH): A Pilot Randomized Clinical Trial.Journal of the National Comprehensive Cancer Network : JNCCN · 2024Trial
- Longitudinal changes in cognitive and physical function and health-related quality of life in older adults with acute myeloid leukemia.Journal of geriatric oncology · 2024Trial
- Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies.Haematologica · 2022Trial
- Trial
- Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia.Blood · 2018Trial
- Frailty and health resource utilization in 5450 adults with acute myeloid leukaemia: A population-based study from Ontario, Canada.British journal of haematology · 2026Article
- Characteristics of patients with newly diagnosed acute myeloid leukemia not receiving treatment.Haematologica · 2026Article
- Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults With Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Aging with leukemia: public health strategies for optimizing quality of life and palliative care in refractory cases.Annals of medicine and surgery (2012) · 2025Review
- CD37 in acute myeloid leukemia: a novel surface target for drug delivery.Blood advances · 2025Article
- A peer support intervention in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT): The STEPP randomized pilot trial design and methods.Contemporary clinical trials · 2025Article
- Challenges in hospice and end-of-life care in the transfusion-dependent patient.Hematology. American Society of Hematology. Education Program · 2024Review
- Top Ten Tips Palliative Care Clinicians Should Know About Acute Myeloid Leukemia.Journal of palliative medicine · 2024Article
- Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundHealth care utilization in older adults (age ≥60 years) with acute myeloid leukemia (AML) has not been well studied.
methodsWe conducted a retrospective analysis of 330 consecutive older patients who were diagnosed with AML between May 1, 2005 and December 23, 2011, at 2 hospitals in Boston to examine their health care utilization and end-of-life care. Using multivariable logistic and linear regression models adjusting for covariates, we also compared health care utilization between patients who received intensive induction chemotherapy (n = 197; cytarabine/ anthracycline combination) versus nonintensive chemotherapy (n = 133; single-agent therapy).
resultsThe median number of hospitalizations for the entire cohort was 4.2 (range, 1-18 hospitalizations). Patients who died spent a mean of 28.3% of their life after diagnosis in the hospital and 13.8% of their life attending outpatient clinic appointments. Although the majority of patients (87.9%) died during the 2-year follow-up period, a minority received palliative care (16.2%) or hospice (23.1%) services. Within 30 days of death, 84.5% of patients were hospitalized, and 61% died in the hospital. Among the patients who died, those who received intensive induction therapy (vs nonintensive therapy) spent 30% more of their life after diagnosis in the hospital (P < .0001) and were less likely to receive hospice services (odds ratio, 0.45; P = .05).
conclusionsThe current findings highlight the intensity of health care utilization among older patients with AML, regardless of treatment modality. Despite the poor prognosis, palliative care and hospice services are rarely used. Future work should study novel health care delivery models to optimize care throughout the course of illness and at the end of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.